SG11201701040XA - Chimeric antigen receptors - Google Patents

Chimeric antigen receptors

Info

Publication number
SG11201701040XA
SG11201701040XA SG11201701040XA SG11201701040XA SG11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA SG 11201701040X A SG11201701040X A SG 11201701040XA
Authority
SG
Singapore
Prior art keywords
chimeric antigen
antigen receptors
receptors
chimeric
antigen
Prior art date
Application number
SG11201701040XA
Other languages
English (en)
Inventor
Gavin Thurston
Andrew J Murphy
Lynn Macdonald
John Mcwhirter
Naxin Tu
Cagan Gurer
Vera Voronina
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201701040XA publication Critical patent/SG11201701040XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201701040XA 2014-09-19 2015-09-18 Chimeric antigen receptors SG11201701040XA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462052947P 2014-09-19 2014-09-19
US201462052901P 2014-09-19 2014-09-19
US201462076836P 2014-11-07 2014-11-07
US201462094603P 2014-12-19 2014-12-19
US201562167650P 2015-05-28 2015-05-28
PCT/US2015/050975 WO2016044745A1 (en) 2014-09-19 2015-09-18 Chimeric antigen receptors

Publications (1)

Publication Number Publication Date
SG11201701040XA true SG11201701040XA (en) 2017-03-30

Family

ID=54261082

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701040XA SG11201701040XA (en) 2014-09-19 2015-09-18 Chimeric antigen receptors

Country Status (13)

Country Link
US (1) US20160081314A1 (enExample)
EP (1) EP3193592A1 (enExample)
JP (1) JP2017529841A (enExample)
KR (1) KR20170083534A (enExample)
CN (1) CN107072184A (enExample)
AU (1) AU2015317370A1 (enExample)
BR (1) BR112017005245A2 (enExample)
CA (1) CA2959428A1 (enExample)
IL (1) IL250536A0 (enExample)
MX (1) MX2017003640A (enExample)
RU (1) RU2017113134A (enExample)
SG (1) SG11201701040XA (enExample)
WO (1) WO2016044745A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN105247042B (zh) 2013-03-15 2021-06-11 普林斯顿大学理事会 用于高通量纯化的方法和设备
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
EP3125934B1 (en) * 2014-03-05 2019-10-23 UCL Business Plc. Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
FR3029449B1 (fr) * 2014-12-03 2017-10-13 Pole De Plasturgie De Lest Dispositif de moulage pour la fabrication de pieces en materiau composite a partir de resine polymere liquide.
MX388784B (es) * 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
RU2017142352A (ru) 2015-05-06 2019-06-06 Снипр Текнолоджиз Лимитед Изменение популяций микроорганизмов и модификация микробиоты
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
DK3359660T3 (en) 2015-10-05 2020-02-17 Prec Biosciences Inc Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
AU2016333898B2 (en) * 2015-10-05 2020-11-12 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
TWI761831B (zh) 2016-04-01 2022-04-21 美商凱特製藥公司 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
DK3436030T3 (da) 2016-04-01 2022-11-21 Kite Pharma Inc Kimæriske receptorer og fremgangsmåder til anvendelse deraf
SG11201808831TA (en) 2016-04-15 2018-11-29 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
CN109640644B (zh) * 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2018011573A1 (en) * 2016-07-12 2018-01-18 Kymab Limited Animals, cells, ligands, polypeptides & methods
EP3504245A4 (en) * 2016-08-23 2020-04-22 The Regents of The University of California PROTEOLYTICLY CLEAVABLE CHIMERAL POLYPEPTIDES AND METHOD FOR USE THEREOF
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
AU2017366739B2 (en) 2016-12-02 2023-11-23 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
KR102630036B1 (ko) 2016-12-23 2024-01-29 마크로제닉스, 인크. Adam9-결합 분자, 및 이것의 사용 방법
US20190359678A1 (en) * 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
EP3608335A4 (en) * 2017-04-05 2020-04-29 XDCExplorer (Shanghai) Co., Ltd. HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
WO2019005957A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE
WO2019028032A1 (en) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
JP2020533957A (ja) 2017-07-31 2020-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃｒｉｓｐｒリポーター非ヒト動物およびその使用
WO2019046052A1 (en) 2017-09-01 2019-03-07 Gpb Scientific, Llc METHODS FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDIC
IL273217B2 (en) * 2017-09-22 2025-04-01 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
IL273424B2 (en) 2017-09-22 2024-09-01 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
IL274179B2 (en) 2017-10-27 2024-02-01 Univ California Targeted replacement of endogenous T cell receptors
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CA3076377A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized trkb locus
SG11202007513PA (en) 2018-02-16 2020-09-29 Kite Pharma Inc Modified pluripotent stem cells and methods of making and use
CN116349651A (zh) 2018-03-19 2023-06-30 瑞泽恩制药公司 使用crispr/cas系统对动物进行转录调制
US20210051929A1 (en) * 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN108424931A (zh) * 2018-03-29 2018-08-21 内蒙古大学 CRISPR/Cas9技术介导山羊VEGF基因定点整合的方法
JP7304888B2 (ja) 2018-04-12 2023-07-07 プレシジョン バイオサイエンシズ，インク． ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN113412117B (zh) 2018-12-12 2025-03-04 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
JP7542822B2 (ja) * 2018-12-27 2024-09-02 国立大学法人京都大学 Ｔ細胞受容体の改変体
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
AU2020286382A1 (en) 2019-06-04 2021-11-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
KR20220042137A (ko) * 2019-07-03 2022-04-04 리제너론 파아마슈티컬스, 인크. 항-뉴욕 식도 편평 세포 암종 1 (ny-eso-1) 항원-결합 단백질 및 이의 사용 방법
US20220267726A1 (en) 2019-07-18 2022-08-25 Gpb Scientific, Inc. Ordered processing of blood products to produce therapeutically active cells
BR112022004458A2 (pt) * 2019-09-12 2022-05-31 Tcr2 Therapeutics Inc Composições e métodos para reprogramação de tcr usando proteínas de fusão
KR20220129566A (ko) 2019-12-28 2022-09-23 지피비 싸이언티픽, 인크 입자 및 세포를 처리하기 위한 미세 유체 카트리지
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
WO2021156277A1 (en) * 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
CN111320703A (zh) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 靶向cd22的嵌合抗原受体及其应用
WO2021190580A1 (en) * 2020-03-26 2021-09-30 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific polypeptide complexes, compositions, and methods of preparation and use
CN114746152A (zh) * 2020-08-23 2022-07-12 应用干细胞有限公司 Hla-f修饰的细胞和方法
JP2024518443A (ja) * 2021-05-07 2024-05-01 センティ バイオサイエンシズ インコーポレイテッド キメラ抗原受容体および使用方法
EP4215042A1 (en) * 2022-01-21 2023-07-26 Max-Delbrück-Centrum für Molekulare Medizin A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116138212B (zh) * 2023-01-11 2024-03-05 江苏省中医院 一种制备细胞因子释放综合征小鼠模型的方法及应用
CN118460446B (zh) * 2024-07-12 2024-11-15 内蒙古自治区农牧业科学院 一种支原体突变株及其制备方法与应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JPS6463394A (en) * 1987-09-04 1989-03-09 Kyowa Hakko Kogyo Kk Novel chimera polypeptide
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6045796A (en) 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8218805B2 (en) 2003-10-11 2012-07-10 Charles Hornback Wireless speaker system for use with ceiling fans
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
AU2005206536B2 (en) 2004-01-16 2010-09-02 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
CA2567814C (en) 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP2009504787A (ja) 2005-08-19 2009-02-05 シーラス コーポレイション 抗体によって媒介される免疫応答の増強
ES2937245T3 (es) 2005-08-23 2023-03-27 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2608604T3 (es) 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
US8225343B2 (en) 2008-01-11 2012-07-17 Sony Computer Entertainment America Llc Gesture cataloging and recognition
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
JP2013523098A (ja) 2010-03-29 2013-06-17 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
US8539547B2 (en) 2010-08-18 2013-09-17 Certes Networks, Inc. Policy selector representation for fast retrieval
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
JP5893258B2 (ja) 2011-03-31 2016-03-23 フェリカネットワークス株式会社 情報処理装置および方法、並びにプログラム
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SMT202100243T1 (it) * 2011-10-28 2021-05-07 Regeneron Pharma Topi con recettori delle cellule t geneticamente modificati
DK2770821T3 (da) 2011-10-28 2017-11-27 Regeneron Pharma Genetisk modificerede major histocompatibility-kompleks-mus
KR101926442B1 (ko) 2011-10-28 2018-12-12 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US9547499B2 (en) 2011-12-09 2017-01-17 Microsoft Technology Licensing, Llc Device configuration with cached pre-assembled driver state
WO2013126726A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JP5920830B2 (ja) 2012-09-28 2016-05-18 シスメックス株式会社 試料調製装置および細胞分析装置
SMT201800435T1 (it) 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
LT2958938T (lt) 2013-02-20 2019-07-25 Regeneron Pharmaceuticals, Inc. Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex

Also Published As

Publication number Publication date
CA2959428A1 (en) 2016-03-24
US20160081314A1 (en) 2016-03-24
KR20170083534A (ko) 2017-07-18
IL250536A0 (en) 2017-03-30
JP2017529841A (ja) 2017-10-12
WO2016044745A1 (en) 2016-03-24
MX2017003640A (es) 2017-10-31
RU2017113134A (ru) 2018-10-19
EP3193592A1 (en) 2017-07-26
BR112017005245A2 (pt) 2017-12-12
CN107072184A (zh) 2017-08-18
AU2015317370A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
IL291292A (en) Chimeric antigen receptors targeting cd-19
IL250536A0 (en) Chimeric antigen receptors
IL251030A0 (en) Chimeric antigen receptors
ZA201704059B (en) Bcma chimeric antigen receptors
ZA201700730B (en) Bcma chimeric antigen receptors
IL254254B (en) chimeric antigen receptor
IL258527A (en) Chimeric Antigen Receptors Against Sorting Group 30
SG11201606790XA (en) Chimeric antigen receptor
GB201617290D0 (en) Novel chimeric antigen receptors
PT3230310T (pt) Recetores de antigénios quiméricos anti-cd70
GB201503742D0 (en) Chimeric antigen receptor
EP3256496A4 (en) Chimeric antigen receptors
HUE056735T2 (hu) Kiméra antigénreceptorok MND promóterrel
GB201411420D0 (en) Antibody constructs
GB201519900D0 (en) Chimeric antigen receptor
HK1240770A1 (zh) 嵌合抗原受体
GB201409761D0 (en) Chimeric antigen receptor
GB201403481D0 (en) Chimeric antigen receptor